Chairman Lee Yun-woo Increases Stake in DaehanPharmaceutical by 0.02% via Open Market Purchase, Signaling Confidence but No Governance Change

Lee Yun-woo, registered executive and de facto controlling shareholder of DaehanPharmaceutical, acquired an additional 1,192 common shares worth approximately 31 million KRW through open market purchases from June 16 to June 22, 2026.
This purchase increased his stake from 24.79% to 24.81%, signaling management's confidence in the company's undervaluation and commitment to responsible management, which is interpreted as a positive signal to the market.
The scale of the increase is only 0.02% of total outstanding shares, so the direct impact on the stock price is negligible, but insider buying by the owner can improve investor sentiment.
[AI Summary]This disclosure is a small open market purchase by the controlling shareholder, resulting in no dilution and indirectly confirming management confidence. It does not involve changes in financial soundness or capital structure, so it has no material impact on shareholder value, but may provide a short-term positive momentum for the stock price.